Total Debt Summary of NeoGenomics, Inc.

NeoGenomics, Inc.'s latest annual total debt in 2023 was 611.67 Million USD , up 0.12% from previous year.
NeoGenomics, Inc.'s latest quarterly total debt in 2024 Q2 was 606.51 Million USD , down -0.27% from previous quarter.
NeoGenomics, Inc. reported annual total debt of 610.92 Million USD in 2022, down -0.3% from previous year.
NeoGenomics, Inc. reported annual total debt of 612.79 Million USD in 2021, up 180.81% from previous year.
NeoGenomics, Inc. reported quarterly total debt of 606.26 Million USD for 2024 Q3, down -0.04% from previous quarter.
NeoGenomics, Inc. reported quarterly total debt of 606.51 Million USD for 2024 Q2, down -0.27% from previous quarter.

Annual Total Debt Chart of NeoGenomics, Inc. (2023 - 2000)

Historical Annual Total Debt of NeoGenomics, Inc. (2023 - 2000)

Year	Total Debt	Total Debt Growth
2023	611.67 Million USD	0.12%
2022	610.92 Million USD	-0.3%
2021	612.79 Million USD	180.81%
2020	218.22 Million USD	64.23%
2019	132.87 Million USD	18.32%
2018	112.3 Million USD	6.52%
2017	105.42 Million USD	-0.7%
2016	106.16 Million USD	48.74%
2015	71.37 Million USD	741.63%
2014	8.48 Million USD	-18.15%
2013	10.36 Million USD	-24.73%
2012	13.76 Million USD	59.84%
2011	8.61 Million USD	26.94%
2010	6.78 Million USD	90.59%
2009	3.56 Million USD	11.71%
2008	3.18 Million USD	195.08%
2007	1.08 Million USD	98.77%
2006	543.37 Thousand USD	0.0%
2005	- USD	0.0%
2004	- USD	-100.0%
2003	590 Thousand USD	4264.55%
2002	13.51 Thousand USD	0.0%
2001	- USD	0.0%
2000	- USD	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	608.18 Million USD	-0.57%
2024 Q3	606.26 Million USD	-0.04%
2024 Q2	606.51 Million USD	-0.27%
2023 FY	611.67 Million USD	0.12%
2023 Q2	609.58 Million USD	-0.12%
2023 Q3	605.69 Million USD	-0.64%
2023 Q1	610.32 Million USD	-0.1%
2023 Q4	611.67 Million USD	0.99%
2022 Q1	613.2 Million USD	0.07%
2022 Q2	611.89 Million USD	-0.21%
2022 Q3	611.57 Million USD	-0.05%
2022 Q4	610.92 Million USD	-0.11%
2022 FY	610.92 Million USD	-0.3%
2021 Q1	584.01 Million USD	167.62%
2021 Q2	588.25 Million USD	0.73%
2021 Q3	612.81 Million USD	4.18%
2021 Q4	612.79 Million USD	-0.0%
2021 FY	612.79 Million USD	180.81%
2020 Q4	218.22 Million USD	-0.52%
2020 Q3	219.36 Million USD	-0.26%
2020 Q1	153.38 Million USD	15.44%
2020 FY	218.22 Million USD	64.23%
2020 Q2	219.93 Million USD	43.38%
2019 Q2	137.46 Million USD	5.02%
2019 Q1	130.89 Million USD	16.55%
2019 Q3	136.4 Million USD	-0.77%
2019 Q4	132.87 Million USD	-2.59%
2019 FY	132.87 Million USD	18.32%
2018 Q3	110.31 Million USD	-20.37%
2018 FY	112.3 Million USD	6.52%
2018 Q2	138.53 Million USD	37.1%
2018 Q1	101.04 Million USD	-4.15%
2018 Q4	112.3 Million USD	1.8%
2017 Q3	105.06 Million USD	-3.89%
2017 Q4	105.42 Million USD	0.35%
2017 FY	105.42 Million USD	-0.7%
2017 Q1	110.98 Million USD	4.54%
2017 Q2	109.3 Million USD	-1.51%
2016 Q1	61.3 Million USD	-14.12%
2016 FY	106.16 Million USD	48.74%
2016 Q4	106.16 Million USD	67.59%
2016 Q3	63.35 Million USD	1.65%
2016 Q2	62.32 Million USD	1.66%
2015 Q3	9.94 Million USD	-1.02%
2015 Q4	71.37 Million USD	617.67%
2015 Q2	10.04 Million USD	-0.38%
2015 Q1	10.08 Million USD	18.92%
2015 FY	71.37 Million USD	741.63%
2014 Q3	8.37 Million USD	-14.36%
2014 Q2	9.77 Million USD	-17.62%
2014 Q4	8.48 Million USD	1.33%
2014 FY	8.48 Million USD	-18.15%
2014 Q1	11.86 Million USD	14.5%
2013 FY	10.36 Million USD	-24.73%
2013 Q4	10.36 Million USD	29.64%
2013 Q3	7.99 Million USD	-8.23%
2013 Q2	8.71 Million USD	-6.44%
2013 Q1	9.31 Million USD	-32.37%
2012 FY	13.76 Million USD	59.84%
2012 Q1	12.01 Million USD	39.54%
2012 Q4	13.76 Million USD	-1.37%
2012 Q2	12.14 Million USD	1.03%
2012 Q3	13.95 Million USD	14.95%
2011 FY	8.61 Million USD	26.94%
2011 Q4	8.61 Million USD	8.7%
2011 Q3	7.92 Million USD	14.31%
2011 Q2	6.93 Million USD	-0.39%
2011 Q1	6.95 Million USD	2.56%
2010 Q3	7.33 Million USD	13.92%
2010 FY	6.78 Million USD	90.59%
2010 Q1	5.9 Million USD	65.92%
2010 Q4	6.78 Million USD	-7.46%
2010 Q2	6.43 Million USD	8.96%
2009 Q1	3.5 Million USD	9.82%
2009 FY	3.56 Million USD	11.71%
2009 Q2	4.25 Million USD	21.69%
2009 Q3	2.56 Million USD	-39.84%
2009 Q4	3.56 Million USD	38.94%
2008 Q4	3.18 Million USD	18.9%
2008 Q2	2.22 Million USD	89.03%
2008 Q1	1.17 Million USD	9.15%
2008 FY	3.18 Million USD	195.08%
2008 Q3	2.68 Million USD	20.28%
2007 Q2	752.53 Thousand USD	0.02%
2007 Q1	752.37 Thousand USD	38.46%
2007 Q4	1.08 Million USD	20.25%
2007 FY	1.08 Million USD	98.77%
2007 Q3	898.18 Thousand USD	19.35%
2006 Q1	1.55 Million USD	0.0%
2006 Q3	2.01 Million USD	16.99%
2006 Q2	1.72 Million USD	10.87%
2006 Q4	543.37 Thousand USD	-73.05%
2006 FY	543.37 Thousand USD	0.0%
2005 Q3	1.26 Million USD	0.0%
2005 FY	- USD	0.0%
2005 Q1	- USD	0.0%
2005 Q2	- USD	0.0%
2005 Q4	- USD	-100.0%
2004 Q3	728.66 Thousand USD	0.0%
2004 FY	- USD	-100.0%
2004 Q2	- USD	-100.0%
2004 Q4	- USD	-100.0%
2004 Q1	715 Thousand USD	21.19%
2003 Q4	590 Thousand USD	0.0%
2003 Q1	274.33 Thousand USD	1929.38%
2003 FY	590 Thousand USD	4264.55%
2003 Q2	- USD	-100.0%
2003 Q3	- USD	0.0%
2002 Q3	- USD	0.0%
2002 Q2	- USD	0.0%
2002 FY	13.51 Thousand USD	0.0%
2002 Q1	- USD	0.0%
2002 Q4	13.51 Thousand USD	0.0%
2001 FY	- USD	0.0%
2001 Q4	- USD	0.0%
2001 Q3	- USD	0.0%
2001 Q1	- USD	0.0%
2001 Q2	- USD	0.0%
2000 Q3	28.51 Thousand USD	0.0%
2000 Q1	31.51 Thousand USD	0.0%
2000 FY	- USD	0.0%
2000 Q4	- USD	-100.0%
2000 Q2	28.51 Thousand USD	-9.52%

Peer Total Debt Comparison of NeoGenomics, Inc.

Name	Total Debt	Total Debt Difference
Aclaris Therapeutics, Inc.	426 Thousand USD	-143486.62%
Applied DNA Sciences, Inc.	1.23 Million USD	-49318.223%
Aspira Women's Health Inc.	2.26 Million USD	-26893.778%
Biodesix, Inc.	60.69 Million USD	-907.858%
BioNexus Gene Lab Corp.	133.39 Thousand USD	-458447.172%
bioAffinity Technologies, Inc.	1.57 Million USD	-38647.237%
bioAffinity Technologies, Inc.	1.57 Million USD	-38647.237%
Bionano Genomics, Inc.	87.94 Million USD	-595.509%
CareDx, Inc	34.22 Million USD	-1687.438%
Check-Cap Ltd.	- USD	-Infinity%
Castle Biosciences, Inc.	15.31 Million USD	-3895.291%
DarioHealth Corp.	29.54 Million USD	-1970.61%
Exact Sciences Corporation	2.55 Billion USD	76.057%
Fulgent Genetics, Inc.	14.9 Million USD	-4003.3%
Guardant Health, Inc.	1.35 Billion USD	54.816%
ICON Public Limited Company	3.93 Billion USD	84.469%
IDEXX Laboratories, Inc.	947.88 Million USD	35.469%
Illumina, Inc.	2.26 Billion USD	72.958%
Intelligent Bio Solutions Inc.	871.44 Thousand USD	-70091.752%
iSpecimen Inc.	196.24 Thousand USD	-311593.096%
Standard BioTools Inc.	98.21 Million USD	-522.828%
MDxHealth SA	41.26 Million USD	-1382.319%
23andMe Holding Co.	76.51 Million USD	-699.424%
Medpace Holdings, Inc.	142.12 Million USD	-330.39%
Myriad Genetics, Inc.	145 Million USD	-321.848%
Mainz Biomed B.V.	7.42 Million USD	-8142.786%
ENDRA Life Sciences Inc.	394.4 Thousand USD	-154989.845%
Neogen Corporation	906.23 Million USD	32.504%
Inotiv, Inc.	417.64 Million USD	-46.46%
Natera, Inc.	441.99 Million USD	-38.391%
OpGen, Inc.	13.04 Million USD	-4589.457%
OPKO Health, Inc.	326.56 Million USD	-87.308%
Psychemedics Corporation	2.29 Million USD	-26517.885%
Prenetics Global Limited	2.36 Million USD	-25715.907%
Prenetics Global Limited	2.36 Million USD	-25715.907%
Precipio, Inc.	1.11 Million USD	-54709.946%
Personalis, Inc.	48.96 Million USD	-1149.293%
RadNet, Inc.	1.49 Billion USD	58.979%
Sera Prognostics, Inc.	1.85 Million USD	-32821.367%
Sotera Health Company	2.32 Billion USD	73.714%
Neuronetics, Inc.	62.47 Million USD	-879.094%
Star Equity Holdings, Inc.	3.6 Million USD	-16848.712%
Star Equity Holdings, Inc.	3.6 Million USD	-16848.712%
Trinity Biotech plc	67.42 Million USD	-807.172%
T2 Biosystems, Inc.	49.49 Million USD	-1135.765%
Twist Bioscience Corporation	94.06 Million USD	-550.245%
Exagen Inc.	23.72 Million USD	-2478.639%

Global Stocks Search

NeoGenomics, Inc. (NEO)

Total Debt Summary of NeoGenomics, Inc.

Annual Total Debt Chart of NeoGenomics, Inc. (2023 - 2000)

Historical Annual Total Debt of NeoGenomics, Inc. (2023 - 2000)

Peer Total Debt Comparison of NeoGenomics, Inc.